Abstract
Introduction There is increasing use of knowledge graphs within medicine and healthcare, but a comprehensive survey of their applications in biomedical and healthcare sciences is lacking. Our primary aim is to systematically describe knowledge graph use cases, data characteristics, and research attributes in the academic literature. Our secondary objective is to assess the extent of real-world validation of findings from knowledge graph analysis.
Methods We conducted this review in accordance with the PRISMA extension for Scoping Reviews to characterize biomedical and healthcare uses of knowledge graphs. Using keyword-based searches, relevant publications and preprints were identified from MEDLINE, EMBASE, medRxiv, arXiv, and bioRxiv databases. A final set of 255 articles were included in the analysis.
Results Although medical science insights and drug repurposing are the most common uses, there is a broad range of knowledge graph use cases. General graphs are more common than graphs specific to disease areas. Knowledge graphs are heterogenous in size with median node numbers 46 983 (IQR 6 415-460 948) and median edge numbers 906 737 (IQR 66 272-9 894 909). DrugBank is the most frequently used data source, cited in 46 manuscripts. Analysing node and edge classes within the graphs suggests delineation into two broad groups: biomedical and clinical. Querying is the most common analytic technique in the literature; however, more advanced machine learning techniques are often used.
Discussion The variation in use case and disease area focus identifies areas of opportunity for knowledge graphs. There is diversity of graph construction and validation methods. Translation of knowledge graphs into clinical practice remains a challenge. Critically assessing the success of deploying insights derived from graphs will help determine the best practice in this area.
Competing Interest Statement
SB owns equity in Owkin Inc.; JZ is employed as a senior informatician by Arcturis Data; HA is the Chief Scientific Officer of Preemptive Medicine and Health Security initiative at Flagship Pioneering UK; NS is cofounder and the Chief Executive of BioCorteX Inc.
Clinical Protocols
Funding Statement
SB acknowledges funding from the Wellcome Trust (102186/B/13/Z), from the Charlotte and Yule Bogue Research Fellowship in honour of Sir Charles Lovatt Evans and A.J. Clark from University College London, and from The Alan Turing Institute Enrichment Scheme. JZ acknowledges funding from the Wellcome Trust (203928/Z/16/Z) and support from the National Institute for Health Research Biomedical Research Centre based at Imperial College NHS Trust and Imperial College London. DGJM was supported by NIHR as an In-Practice Fellow (NIHR301988). AN gratefully acknowledges the support of the SPARK Fellowship from the Center for Public Service and Engaged Scholarship at Harvard College. MZ gratefully acknowledges the support of the National Institutes of Health under R01HD108794, U.S. Air Force under FA8702-15-D-0001, awards from Harvard Data Science Initiative, Amazon Faculty Research, Google Research Scholar Program, Bayer Early Excellence in Science, AstraZeneca Research, Roche Alliance with Distinguished Scientists, and Kempner Institute for the Study of Natural and Artificial Intelligence.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
